Flatiron Health

flatiron.com →

-15%

est. 2Y upside i

HealthcareSeries C

Rank

#2639

Sector

Health Care Technology

Est. Liquidity

~2Y

Data Quality

Data: Medium

Flatiron Health, a subsidiary of Roche, presents a moderate upside opportunity for a job seeker, primarily driven by the potential for a divestiture by Roche within the next two years.

Last updated: March 10, 2026

Bull (25%)+100%

A highly strategic buyer, unburdened by the 'Roche discount,' acquires Flatiron Health at a significant premium, recognizing the unique value of its proprietary oncology data, EHR platform, and new AI-powered global datasets. This pushes the valuation to $3.8B, or ~7.6x revenue, as the company expands its market penetration and leverages new partnerships.

Base (50%)+35%

Flatiron Health is acquired by a strategic buyer (e.g., another healthcare tech firm or private equity) at a modest premium, as the 'Roche discount' is removed and the core EHR and real-world data assets are valued. The partial divestiture of the clinical research business allows for a more focused entity, leading to a valuation of approximately $2.565B, or ~5.1x revenue.

Bear (25%)-35%

The sale process proves challenging, or increased competition from incumbents like Epic and Cerner, coupled with the impact of the clinical research business divestiture, leads to a lower valuation. Roche struggles to find a buyer at the desired price, resulting in an acquisition at approximately $1.235B, or ~2.5x revenue, significantly impacting common stock value.

Est. time to liquidity~2.0 years

Preference Stack Risk

high

Funding Intensity

17%

Prior to its acquisition by Roche, Flatiron Health raised $314M in total funding against an acquisition valuation of $1.9B, representing a 16.5% investor take ratio.

Dilution Risk

low

As a subsidiary of Roche, the primary dilution risk from new funding rounds is minimal; the main risk is the valuation at a potential divestiture.

Secondary Liquidity

none

There is no active secondary market for equity in Flatiron Health as it is a privately held subsidiary of Roche.

View all 23 open roles at Flatiron Health →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Flatiron Health's data — designed to show you've done your homework.

  • 1

    “Given Roche's reported consideration of selling Flatiron Health, how is the company preparing for a potential change in ownership, and what are the strategic priorities for the business in the interim?”

  • 2

    “With the recent sale of the Clinical Research Business to Paradigm Health, how does Flatiron Health plan to leverage its core EHR and real-world data assets to drive continued growth and innovation, particularly with the expansion of AI-powered global datasets?”

  • 3

    “Considering the current market conditions and the potential for a liquidity event within a 2-year horizon, how does the company envision the equity value for employees evolving, and what are the key milestones that would drive that value?”

Community

Valuation Sentiment

Our model estimates -15% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.